hrp0097p1-213 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Age at diagnosis of XLH amongst children with and without a family history: Findings from the International XLH Registry

Uday Suma , Sandilands Kerry , Williams Angela , Mughal M.Zulf

Background: X-linked hypophosphatemia (XLH) is a rare, progressive, genetic phosphate wasting disorder leading to rickets, lower limb deformities as well as short and disproportionate stature. The condition is inherited in the majority, however spontaneous mutations are reported in ≈30% of cases. Its rarity, coupled with its diverse clinical manifestations, may lead to delayed diagnosis and subsequently delayed treatment initiation. The objective of this an...

hrp0098p1-120 | Bone, Growth Plate and Mineral Metabolism 2 | ESPE2024

Health-related quality of life (HRQL) in paediatric patients with X-linked hypophosphatemia (XLH) in France: analysis of observational real-world registry data

Amouroux Cyril , Bacchetta Justine , Harambat Jerome , Gueorguieva Iva , Salles Jean-Pierre , Sandilands Kerry , Rylands Angela , Williams Angela , Ishii Haruka , Dent Jennifer , Nixon Annabel , Linglart Agnès

Background: X-linked hypophosphatemia (XLH) is a rare, progressive, phosphate-wasting disorder that compromises skeletal development in childhood. The international XLH registry (NCT03193476) is a non-interventional, observational, real-world data collection programme established in August 2017 in Europe and Israel, with enrolment open to patients of any age with XLH.Objectives: To describe real-world registry data on HR...

hrp0098p1-116 | Bone, Growth Plate and Mineral Metabolism 2 | ESPE2024

Health related quality of life (HRQoL) of adolescents with XLH treated with burosumab at the end of skeletal growth (EoSG.

Saraff Vrinda , Arango Sancho Pedro , Bacchetta Justine , Linglart Agnès , Burren Christine , Chinoy Amish , Dharmaraj Poonam , Amelia Gómez Llorente Maria , David González Rodríguez Juan , Gueorguieva Iva , Haf Davies Elin , Hayes Wesley , Komarzynski Sandra , Ríos Duro Héctor , J Rylands Angela , Sandilands Kerry , Hardie Emily , Ishii Haruka , Schnabel Dirk , Selveindran San , M Boot Annemieke

Introduction: X-linked hypophosphatemia (XLH) is a rare, progressive, genetic disorder causing phosphate wasting; hence symptoms in children include impaired growth, lower limb deformities, chronic pain and impaired physical function. Health-related quality of life (HRQoL) of patients with XLH on conventional therapy is lower than that of the general population. Burosumab has been shown to improve HRQoL in younger children and adults, but its effects in adoles...